Diclazepam (2′-Chlorodiazepam, Ro5-3448)

PRODUCT DETAILS TABLE

Diclazepam (2′-Chlorodiazepam, Ro5-3448)

represents a sophisticated chlorinated benzodiazepine derivative that has emerged as a critical research tool in pharmacological studies examining GABAergic neurotransmission, benzodiazepine receptor pharmacology, and anxiolytic mechanism investigations. As a structural analog of diazepam featuring a chlorine substituent at the 2′-position of the phenyl ring, Diclazepam offers distinct pharmacokinetic and pharmacodynamic properties that differentiate it from parent compounds and other benzodiazepine analogs. Biosynlab delivers pharmaceutical-grade Diclazepam with certified ≥99.0% purity, supporting cutting-edge research across USA, United Kingdom, European Union, and international scientific markets.

The strategic chlorination at the ortho position of the pendant phenyl ring fundamentally alters the compound’s lipophilicity, metabolic stability, and binding affinity at GABA-A receptor subtypes compared to diazepam. This structural modification creates unique pharmacological characteristics that make Diclazepam invaluable for comparative studies with other benzodiazepines including diazepam, flubromazepam, clonazepam, and etizolam. Researchers at institutions in London, Berlin, Amsterdam, New York, and Boston utilize Biosynlab Diclazepam for investigations into GABA receptor subtype selectivity, contributing to the broader understanding of benzodiazepine pharmacology and potential therapeutic applications in anxiety disorders, epilepsy, and muscle relaxation.